The Psoriasis and Psoriatic Arthritis Pocket Guide - Treatment Algorithms and Management Options

This is the fifth edition of The Psoriasis and Psoriatic Arthritis Pocket Guide: Treatment Algorithms and Management Options. Since the publication of the fourth edition, several new psoriasis treatments have become available, and the medical community has more experience with biological treatments in the management of psoriasis. The National Psoriasis Foundation has revised this publication again to provide more up-to-date guidance for managing patients with moderate to severe psoriasis and to put the role of biologics, no longer new drugs, into perspective.

Download for Free

Abby S. Van Voorhees, M.D.
Chair of Dermatology
Eastern Virginia Medical School
Norfolk, VA

Steven R. Feldman, M.D., Ph.D.
Professor of Dermatology, Pathology & Public Health Sciences
Wake Forest School of Medicine
Winston-Salem, NC

Mark G. Lebwohl, M.D.
Professor and Chairman, Department of Dermatology
Mount Sinai School of Medicine
New York, NY

Arthur Mandelin, M.D., Ph.D.
Assistant Professor, Department of Medicine - Division of Rheumatology
Northwestern University Feinberg School of Medicine
Chicago, IL

Christopher Ritchlin, M.D., MPH
Chief, Department of Medicine, Allergy/Immunology and Rheumatology (SMD)
University of Rochester Medical Center
Rochester, NY

TREATING PATIENTS IN PRACTICE

Patients should be fully educated about all aspects of their disease, including all potential systemic-related disorders. Each patient should also receive a specific, personalized treatment plan.

OBJECTIVES

After studying this handbook, physicians should be able to:

  • Define the severity of psoriasis and develop an appropriate therapy plan.
  • Explain the profound emotional, social and physical impact psoriatic disease has on the patient.
  • Understand the important comorbidities associate with psoriasis.
  • Differentiate psoriasis from other diseases after evaluating patients who present with similar types of skin lesions.
  • Diagnose patients who have moderate disease (3 percent to 10 percent body involvement) and severe disease (>10 percent body involvement)

Sponsor Acknowledgements

The National Psoriasis would like to thank the following sponsors of the The Psoriasis and Psoriatic Arthritis Pocket Guide:

Bristol-Myers Squibb
Celgene
Lilly